A new nanoparticle can multitask as a drug courier and a delivery reporter by glowing when it dumps its cargo inside tumour cells. The technique could allow doctors to see exactly which cells have successfully received a drug 鈥� if it gets approval for use in humans.
鈥淨uantum dots鈥� are reflective crystals about 1000th of the width of a human hair. They show much promise as medicinal tools due to their extremely bright fluorescence and the ability to carry other molecules on their surface. Until now, however, quantum dots have been continually fluorescent, regardless of which tissue they may have reached, or what job they may have done.
Using cell culture experiments, , who is based at Brigham and Women鈥檚 Hospital, and colleagues at Harvard Medical Schoolat Harvard Medical School and his colleagues have now managed to create quantum dots that only switch this fluorescence on when they enter the target cells and delivered the drug.
Advertisement
Absorbed light
Key to the design are molecules called aptamers that sit on the quantum dot鈥檚 surface. Made of nucleic acids, like DNA, and looped like hairpins, aptamers can bind to specific target molecules. In this case, the ends of the aptamers recognise molecules only found on the outside of prostate cancer cells, while the stems accommodate molecules of the anti-cancer drug doxorubicin (dox).
鈥淣ormally, dox is fluorescent, but when it binds to the aptamer, the interaction between the two molecules switches the fluorescence off,鈥� explains Farokhzad. 鈥淒ox also absorbs all the light reflected from the quantum dot, so that then doesn鈥檛 fluoresce either.鈥�
Only when the nanoparticle has found and entered a cancer cell does it lights up again. This is because the dox is removed from the aptamers, allowing the dot to recover its fluorescence. In the lab, the quantum dots鈥� coloured light can be detected with a fluorescence microscope.
Safer therapy
Since the aptamers also ensure that the drug only reaches cancer cells, the side effects for other cells are much lower than if the drug were to diffuse directly through a cell鈥檚 membrane, as with conventional chemotherapy. Farokhzad believes that by varying the molecules used, his system can be adapted to target a wide range of diseases.
Alison Ross, science information officer at Cancer Research UK, says: 鈥淯sing nanotechnology to target drugs to cancer cells is an exciting technique and the nanoparticles engineered in this study are smarter than ever before.鈥� But she adds that 鈥渕ore research is needed to discover whether these particles could be used to benefit cancer patients in the future鈥�.
As a next step, Farokhzad aims to test the particles in animals with prostate cancer.
Journal reference: Nano Letters,
Cancer 鈥� Learn more about one of the world鈥檚 biggest killers in our comprehensive special report.
Nanotechnology 鈥� Follow the emergence of a new technology in our continuously updated .
